<DOC>
	<DOCNO>NCT00263887</DOCNO>
	<brief_summary>The goal trial explore utility evaluate emphysema progression CT scan measure lung density 2 year period weekly infusion either placebo human alpha-1-antitrypsin ( AAT ; Prolastin® ) . Exacerbation data record patient diary also collect . All efficacy data analyze potential use evaluate Prolastin efficacy clinical trial .</brief_summary>
	<brief_title>Alpha-1-Antitrypsin ( AAT ) To Treat Emphysema In AAT-Deficient Patients ( EXACTLE )</brief_title>
	<detailed_description>This one one randomize , placebo-controlled , clinical , exploratory study aim collect information possible clinical endpoint i.e. , progression emphysema lung density measurement CT scan frequency exacerbation could use subsequent placebo control clinical trial . Progression disease investigate 80 patient alpha-1-antitrypsin deficiency , treat human alpha-1-antitrypsin ( AAT ; Prolastin® ) placebo weekly two year analyze effect treatment lung density exacerbation . Targeted augmentation therapy weekly infusion Prolastin® dose 60 mg/kg body weight ( range 51.72 71.43 mg per kg body weight ) . Therefore , study focus several question : - Is 15th percentile point calculate analysis CT lung histogram useful endpoint clinical trial AAT deficiency ? - Is quantitation exacerbation AAT-deficient patient useful endpoint clinical trial AAT deficiency ? - Are significant difference treatment favor Prolastin® ?</detailed_description>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Patient pulmonary emphysema due severe congenital AAT deficiency phenotype protease inhibitor Z ( PiZ ) rare genotype ( MS , MZ SZ ) AAT serum level &lt; 11 micron ( µM ) &lt; 80 mg/dL ( status confirm phenotyping genotyping ) Inspiratory capacity ( VC ERV ) &gt; 1.2 L force expiratory volume one second ( FEV1 ) &lt; 80 % predict value post bronchodilator FEV1/VC &lt; 70 % predict value postbronchodilator transfer factor carbon monoxide ( KCO ) &lt; 80 % predict value postbronchodilator History least one exacerbation past 2 year Written inform consent FEV1 &lt; 25 % predict value postbronchodilator Augmentation therapy one month plasmaderived human alpha 1antitrypsin ( AAT ) within last 2 year History lung transplant Any lung surgery within past 2 year On thoracic surgery wait list Diagnosis liver cirrhosis Severe concomitant disease Active pulmonary infection/exacerbations within last month Active smoking last 6 month plasma positive cotinine Body weight &lt; 42 kg &gt; 92 kg Pregnancy lactation Women childbearing potential without adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>alpha 1 proteinase inhibitor</keyword>
	<keyword>alpha1 proteinase inhibitor</keyword>
	<keyword>congenital emphysema</keyword>
	<keyword>replacement therapy</keyword>
</DOC>